| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,126 | -19,142 |
| Depreciation and amortization | 89 | 54 |
| Net accretion of discounts/premiums on debt securities | -476 | -363 |
| Share-based compensation | 4,540 | 3,493 |
| Equity method investment, realized gain on disposal | 22,350 | - |
| Loss on investment in joint venture | -874 | -874 |
| Prepaid expenses, operating lease right-of-use assets and other current assets | 2,858 | 2,085 |
| Accounts payable | -9 | -159 |
| Accrued expenses and operating lease liabilities | -1,182 | -832 |
| Deferred revenue | -636 | -424 |
| Net cash used in operating activities | -25,134 | -18,584 |
| Purchases of marketable securities | 10,622 | 9,884 |
| Proceeds from maturities of marketable securities | 35,465 | 25,500 |
| Proceeds from sale of common stock received from sale of joint venture | 20,000 | - |
| Investment in joint venture | 1,500 | 1,500 |
| Net cash provided by investing activities | 43,343 | 14,116 |
| Proceeds from the issuance of common stock from a securities purchase agreement | 0 | 0 |
| Proceeds from the issuance of common stock under the stock purchase plan | 10 | 10 |
| Payments of offering costs | 0 | 0 |
| Net cash provided by financing activities | 10 | 10 |
| Net increase in cash and cash equivalents | 18,219 | -4,458 |
| Cash and cash equivalents at beginning of period | 13,903 | - |
| Cash and cash equivalents at end of period | 32,122 | - |
Rallybio Corp (RLYB)
Rallybio Corp (RLYB)